CIBC Asset Management Inc Raises Stock Holdings in Zoetis Inc. $ZTS

CIBC Asset Management Inc lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 9.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 274,299 shares of the company’s stock after acquiring an additional 22,804 shares during the period. CIBC Asset Management Inc’s holdings in Zoetis were worth $34,470,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the fourth quarter worth $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the third quarter worth $31,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the fourth quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in Zoetis in the fourth quarter worth $32,000. Finally, Holos Integrated Wealth LLC purchased a new stake in Zoetis in the fourth quarter worth $32,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market commentary says Zoetis could still be a value opportunity, with one analysis describing the stock as a potential deep-value play with significant upside if the business stabilizes.
• Neutral Sentiment: Zoetis presented at the William Blair Growth Stock Conference, but no major new operating update from that event was highlighted in the headlines provided.
• Negative Sentiment: Multiple law firms announced or reminded investors about a class-action lawsuit alleging securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, with several notices urging shareholders to seek lead-plaintiff status by July 27, 2026. These repeated legal alerts can weigh on the stock. Article Title
• Negative Sentiment: One article said Zoetis has underperformed its industry peers over the past year, reinforcing concerns about recent relative stock performance.
• Negative Sentiment: Investor notices from Robbins Geller, Levi & Korsinsky, the Schall Law Firm, Howard G. Smith, Bernstein Liebhard, The Gross Law Firm, DJS Law Group, and others all highlighted the ongoing lawsuit, increasing headline risk for ZTS.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock valued at $886,384 over the last three months. Company insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ZTS shares. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Stifel Nicolaus decreased their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America raised their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Finally, Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Price Performance

Zoetis stock opened at $77.51 on Thursday. Zoetis Inc. has a one year low of $72.38 and a one year high of $171.52. The business has a fifty day moving average price of $101.99 and a 200-day moving average price of $116.09. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a market capitalization of $32.49 billion, a P/E ratio of 12.85, a PEG ratio of 1.25 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the business earned $1.48 earnings per share. Zoetis’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.89 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.